advocacy

Opinions+ By Giacomo Chiesi

More pharma companies should make the move toward becoming environmentally sustainable

First Opinion By Chelsea Clinton, Terry McGovern, and Micaela Martinez

End fracking exemptions, a threat to maternal and public health

First Opinion By Travis Whitfill

To create value, pharma companies should prioritize innovation, not shareholders

First Opinion By Alice Hill and Wayne C. Koff

Climate change and human immunity: invest now or pay more later

First Opinion By Diane O'Leary

Needed for long Covid: a less authoritarian approach to understanding, treatment

Politics By Nicholas Florko

PhRMA chief talks strategy — and he’s surprisingly optimistic about drug pricing reform

First Opinion By Isabel Alexander

Autism: awareness, acceptance, and the places in between

First Opinion By Nicholas Freudenberg

Corporate versus public control of science and technology: Forging a framework for the 21st Century

First Opinion By Ann C. Greiner and Elizabeth Mitchell

Building back better requires strengthening primary care

First Opinion By Jennifer Olsen

Caregivers are missing from the long Covid conversation

First Opinion By Hil Moss

What cancer survivorship can teach us about Covid-19

In the Lab By Rebecca Sohn

The new leader of 500 Women Scientists on finding community and supporting women of color in STEMM

First Opinion By Andrew Peterson, Jason Karlawish, and Emily Largent

A monument to our monumental suffering can help America heal from this pandemic

First Opinion By Stanley Plotkin, Norman Baylor, and Keona Jeane Wynne

The U.S. needs a National Vaccine Day

First Opinion By Amir Kalali and Craig Lipset

Decentralized clinical trials: Collaboration is needed to drive their adoption and impact

First Opinion By Nandita Murukutla and Rebecca Perl

Governments’ alcohol subsidies are harmful to public health

First Opinion By Daniel Carpenter and Gregg Gonsalves

The stakes for choosing the right FDA commissioner couldn’t be higher

Politics By Nicholas Florko

Some Trump staffers face a slightly different revolving door

Politics By Lev Facher

Major health companies and trade groups suspend campaign contributions after Capitol riot

First Opinion By Melissa J. Perry

Stop sidelining science. Bring back federal scientific advisory committees

First Opinion By Abraar Karan, Ranu Dhillon, and Devabhaktuni Srikrishna

Along with vaccine rollouts, the U.S. needs a National Hi-Fi Mask Initiative

First Opinion By Vineet Arora, Tricia Pendergrast, and Shikha Jain

Doctors on social media are being cyberbullied and sexually harassed. It’s time to change that

Politics By Lev Facher

Federal judge places restraining order on Trump’s latest drug pricing rule

Politics By Lev Facher

PhRMA took in a record $527 million in 2019, new records show

Politics By Nicholas Florko

Biden’s HHS pick, Becerra, has taken in more campaign cash from health groups than any other industry